Totrombopag

• Description :

  Totrombopag is an orally effective thrombopoietin receptor (TpoR) agonist. By activating TpoR, Totrombopag initiates an intracellular signaling cascade mediated by JAK2 kinase and the transcription factor Stat5, a signaling process that is the primary mechanism regulating megakaryocyte growth and differentiation into platelets. Totrombopag can be used to study platelet production and megakaryocyte biology[1].

• UNSPSC :

  12352005

• Target :

  Thrombopoietin Receptor

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Others

• Assay Protocol :

  https://www.medchemexpress.com/totrombopag.html

• Concentration :

  10mM

• Purity :

  99.00

• Solubility :

  DMSO : 50 mg/mL (ultrasonic)

• Smiles :

  O=C1N(C2=CC=C(C)C(C)=C2)N=C(C1/N=N/C3=C(O)C(C4=CC(C5=NN=NN5)=CC=C4)=CC=C3)C

• Molecular Formula :

  C25H22N8O2

• Molecular Weight :

  466.49

• References & Citations :

  [1]Alper P B, et al. Discovery and biological evaluation of benzo [a] carbazole-based small molecule agonists of the thrombopoietin (Tpo) receptor[J]. Bioorganic & medicinal chemistry letters, 2008, 18 (19) : 5255-5258.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• CAS Number :

  [376592-42-6]